We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+27.77%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$1.42B
AUM Growth
+$256M
(+22%)
Cap. Flow
+$65.4M
Cap. Flow
% of AUM
4.61%
Top 10 Holdings %
Top 10 Hldgs %
29.29%
Holding
112
New
24
Increased
30
Reduced
36
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$48.1M |
| 2 |
Replimune Group
REPL
|
+$27.8M |
| 3 |
Maravai LifeSciences
MRVI
|
+$27.3M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$25.6M |
| 5 |
Certara
CERT
|
+$22.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$51M |
| 2 |
HMSY
HMS Holdings Corp.
HMSY
|
+$18.7M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
+$18.2M |
| 4 |
Aprea Therapeutics
APRE
|
+$17.9M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
+$16.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.8% |
| 2 | Industrials | 1.99% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Pfizer
PFE
$145B
| $3.49M | 0.25% |
94,900
-23,043
| -20% | -$845K |
|
|
NCNA
77
NuCana
NCNA
$5.79M
| $3.37M | 0.24% |
150
| – | – |
|
78
Biogen
BIIB
$30.8B
| $3.13M | 0.22% |
12,782
-9,850
| -44% | -$2.54M |
|
79
Regeneron Pharmaceuticals
REGN
$78.3B
| $2.23M | 0.16% |
4,620
-18,310
| -80% | -$9.88M |
|
|
MTEM
80
DELISTED
Molecular Templates, Inc.
MTEM
| $2.11M | 0.15% |
14,967
+3,000
| +25% | +$443K |
|
81
Sotera Health
SHC
$5.16B
| $2.05M | 0.14% |
+74,618
| New | +$2M |
|
82
Stryker
SYK
$129B
| $1.91M | 0.13% |
+7,800
| New | +$1.77M |
|
83
Boston Scientific
BSX
$71.1B
| $1.81M | 0.13% |
50,226
-326,761
| -87% | -$11.8M |
|
84
Gilead Sciences
GILD
$168B
| $1.72M | 0.12% |
29,550
-35,350
| -54% | -$2.13M |
|
85
Danaher
DHR
$137B
| $1.67M | 0.12% |
8,460
| – | – |
|
86
Illumina
ILMN
$30.7B
| $1.51M | 0.11% |
4,184
-797
| -16% | -$254K |
|
|
87
Aprea Therapeutics
APRE
$7.42M
| $805K | 0.06% |
8,184
-37,600
| -82% | -$17.9M |
|
88
Incyte
INCY
$24.4B
| $752K | 0.05% |
8,640
-130,134
| -94% | -$11.3M |
|
89
argenx
ARGX
$52.8B
| $735K | 0.05% |
2,500
| – | – |
|
|
HZNP
90
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $693K | 0.05% |
+9,475
| New | +$704K |
|
91
Zai Lab
ZLAB
$2.09B
| $528K | 0.04% |
3,900
+1,200
| +44% | +$122K |
|
92
Aligos Therapeutics
ALGS
$29.4M
| $517K | 0.04% |
+748
| New | +$364K |
|
93
Dr. Reddy's Laboratories
RDY
$10.1B
| $460K | 0.03% |
32,270
+5,500
| +21% | +$74.1K |
|
94
BridgeBio Pharma
BBIO
$16.1B
| $427K | 0.03% |
+6,000
| New | +$289K |
|
|
KLRS
95
Kalaris Therapeutics
KLRS
$103M
| $375K | 0.03% |
424
-11,654
| -96% | -$8.97M |
|
96
Kodiak Sciences
KOD
$2.68B
| $242K | 0.02% |
+1,650
| New | +$184K |
|
97
4D Molecular Therapeutics
FDMT
$536M
| $217K | 0.02% |
+5,224
| New | +$216K |
|
|
AMED
98
DELISTED
Amedisys
AMED
| – | – |
-15,825
| Closed | -$3.74M |
|
99
Assembly Biosciences
ASMB
$524M
| – | – |
-76,349
| Closed | -$15.1M |
|
100
Castle Biosciences
CSTL
$953M
| – | – |
-18,500
| Closed | -$952K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
TGM
BIS
Sectoral Asset Management's Q4 2020 Portfolio in Review
As of Q4 2020, Sectoral Asset Management held 112 positions worth $1.42B, up 22% from $1.16B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Sectoral Asset Management deployed $65.4M of net new capital in Q4 2020, opening 24 new positions and adding to 30 existing holdings. Its largest new stake was Atea Pharmaceuticals: 1,492,090 shares worth $62.3M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Aprea Therapeutics, an estimated $17.9M trimmed.
- Sectoral Asset Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,492,090 shares worth $62.3M.
- Sectoral Asset Management added most to Tandem Diabetes Care in Q4 2020, an estimated $25.6M increase.
- Sectoral Asset Management's biggest Q4 2020 reduction was Aprea Therapeutics, cutting an estimated $17.9M.
- Sectoral Asset Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $51M.
- Sectoral Asset Management's ten largest holdings make up 29% of its $1.42B portfolio in Q4 2020.
- Sectoral Asset Management opened 24 new positions and closed 15 in Q4 2020.
- Sectoral Asset Management's portfolio value rose 22% quarter-over-quarter to $1.42B.
Based on Sectoral Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.